Active Ingredient(s): Inebilizumab-cdon
FDA Approved: * June 11, 2020
Pharm Company: * VIELA BIO
Category: Vision / Eye Health

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Uplizna Overview

Inebilizumab, sold under the brand name Uplizna, is a medication for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults.[2][3][1] The most common adverse reactions include urinary tract infection, headache, joint pain (arthralgia), nausea and back pain.[2][1] Inebilizumab is a humanized mAb that binds to and depletes CD19+ B cells including plasmablasts and plasma cells.[1] T...

Read more Uplizna Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Inebilizumab

Recent Uplizna Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Injection: 100mg/10ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Uplizna: (1 result)

Sorted by National Drug Code
  • 72677-551 Uplizna 10 mg/ml Intravenous Injection by Viela Bio, Inc.

Other drugs which contain Inebilizumab-cdon or a similar ingredient: (1 result)